|By PR Newswire||
|August 5, 2014 02:27 PM EDT||
CHARLOTTESVILLE, Va., Aug. 5, 2014 /PRNewswire/ -- HemoSonics, a medical diagnostic company developing a novel point-of-care instrument to measure coagulation, announced today that it has named Timothy J. Fischer as President and Chief Executive Officer. Fischer has been a pioneer in the in vitro diagnostics industry in the fields of hematology, oncology and pathology for the past 25 years. He has led the design, development and commercialization of dozens of novel diagnostic products. He holds over 40 patents and has authored numerous publications.
"We are pleased and fortunate to have Tim leading our Company as we turn the corner to commercialization," said William Moffitt, Chairman of the Board of Managers for HemoSonics. "His extensive knowledge of hemostasis and his experience in building high performing product development teams will enable us to fulfill our vision of delivering critical patient information at the point of care."
Prior to joining HemoSonics, Fischer served as Chief Operating Officer for LipoScience, a publicly traded in vitro diagnostics company. At LipoScience, he led the successful development of the Vantera® Clinical Analyzer from concept through development, regulatory approval and market adoption. Before joining LipoScience, he served as Vice President of Development for the Women's Health and Cancer business unit at Becton Dickinson (BD) and as the Vice President of Product Development for TriPath Oncology.
"HemoSonics' novel technology enables an unparalleled product that will save lives and reduce healthcare costs by providing comprehensive information in an easy to use format," said Fischer. "I am thrilled to be part of a team that will revolutionize hemostasis testing and directly impact patient care in the critical care setting."
Fischer holds a Bachelor of Science degree in Biology from Indiana University.
About HemoSonics, LLC
HemoSonics, LLC (http://hemosonics.com), an in vitro diagnostics company, is developing and commercializing a novel ultrasound technology to address a significant unmet need in critical patient care. Bleeding and clotting disorders are a major cause of morbidity and mortality, leading to complications, worse outcomes and longer hospital stays. HemoSonics is developing a platform and assays to identify coagulation dysfunctions in whole blood at the point-of-care in acute care settings, enabling physicians to improve quality of care while reducing overall healthcare costs.
HemoSonics' technology and products are currently labeled as Research Use Only and are not intended for clinical use at this time.
SOURCE HemoSonics, LLC
Oct. 23, 2016 10:00 AM EDT Reads: 3,991
Oct. 23, 2016 09:45 AM EDT Reads: 776
Oct. 23, 2016 09:45 AM EDT Reads: 2,471
Oct. 23, 2016 09:45 AM EDT Reads: 1,004
Oct. 23, 2016 09:45 AM EDT Reads: 1,870
Oct. 23, 2016 09:30 AM EDT Reads: 3,811
Oct. 23, 2016 09:30 AM EDT Reads: 2,118
Oct. 23, 2016 09:15 AM EDT Reads: 2,061
Oct. 23, 2016 09:00 AM EDT Reads: 4,453
Oct. 23, 2016 08:30 AM EDT Reads: 1,336
Oct. 23, 2016 08:15 AM EDT Reads: 4,414
Oct. 23, 2016 08:00 AM EDT Reads: 5,675
Oct. 23, 2016 08:00 AM EDT Reads: 8,324
Oct. 23, 2016 07:00 AM EDT Reads: 4,098
Oct. 23, 2016 06:30 AM EDT Reads: 4,741